Overview

Dose Finding Study of MCI-186 in Acute Ischemic Stroke

Status:
Terminated
Trial end date:
2018-05-14
Target enrollment:
Participant gender:
Summary
To investigate the efficacy and safety of MCI-186 (bolus followed by continuous infusion) in acute ischemic stroke patients through a double-blind, parallel-group comparison with the existing MCI-186 dosing regimen (administration twice daily for 14 days) as the control.
Phase:
Phase 2
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Antipyrine
Edaravone
Phenylmethylpyrazolone